RxDoctor Payments Data

Laquita Bain

Family · Corinth, MSNPI 1437238938

Payments from drug & device makers

$7,690in general payments, 2019–2025

Across 513 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$702
  • Lilly USA, LLC$426
  • Amgen$387
  • Novo Nordisk$376
  • GSK$360
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,690 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$184,882
Medicare patients
604
Services billed
11,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$76,609
EliquisApixaban81$59,442
JardianceEmpagliflozin29$32,736
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,652
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$24,302
TrulicityDulaglutide16$22,306
Tresiba Flextouch U-200Insulin Degludec14$22,229
FarxigaDapagliflozin Propanediol21$15,242
Fiasp FlextouchInsulin Aspart (Niacinamide)12$11,159
MounjaroTirzepatide11$11,144
Tresiba Flextouch U-100Insulin Degludec14$9,160
JanuviaSitagliptin Phosphate14$8,135
Xigduo XrDapaglifloz Propaned/Metformin12$6,992
GemtesaVibegron12$5,500
Gabapentin316$3,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$376$76,60947 claims
PfizerEliquis$702$59,44281 claims
AstraZenecaBreztri Aerosphere, Farxiga$203$39,54438 claims
Lilly USA, LLCTrulicity, Mounjaro$426$33,45027 claims
Boehringer IngelheimJardiance$111$32,73629 claims
GSKTrelegy Ellipta$360$30,65239 claims
MerckJanuvia$62$8,13514 claims
Sumitomo Pharma America, Inc.Gemtesa$36$5,50012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$2,094255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Corinth

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →